These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy. Salem ML Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701 [TBL] [Abstract][Full Text] [Related]
69. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Saxena M; Bhardwaj N Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279 [TBL] [Abstract][Full Text] [Related]
71. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
72. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338 [TBL] [Abstract][Full Text] [Related]